NASDAQ: AVTEAerovate Therapeutics Inc Stock
$2.75+0.07 (+2.61%)
Updated Apr 17, 2025
AVTE Price
$2.75
Fair Value Price
$1.17
Market Cap
$79.71M
52 Week Low
$1.25
52 Week High
$25.29
P/E
-1.13x
P/B
1.04x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$69.63M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$71M
Beta
1.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AVTE Overview
Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company developing drugs to treat rare cardiopulmonary diseases. Pulmonary Arterial Hypertension is a rare progressive and often fatal cardiopulmonary disease affecting both the heart and lungs. Aerovate's lead program, AV-101, is an inhalable dry to address the underlying hyperproliferation of cells within the narrowed arteries of the lungs. Aerovate Therapeutics was incorporated in 2018 and is headquartered in Waltham, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AVTE's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AVTE
Ranked#238 of 463
Ranked#238 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important AVTE news, forecast changes, insider trades & much more!
AVTE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AVTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AVTE ($2.75) is overvalued by 135.8% relative to our estimate of its Fair Value price of $1.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AVTE ($2.75) is not significantly undervalued (135.8%) relative to our estimate of its Fair Value price of $1.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AVTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AVTE due diligence checks available for Premium users.
Valuation
AVTE fair value
Fair Value of AVTE stock based on Discounted Cash Flow (DCF)
Price
$2.75
Fair Value
$1.17
Overvalued by
135.80%
AVTE ($2.75) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AVTE ($2.75) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AVTE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AVTE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.13x
Industry
-177.72x
Market
27.98x
AVTE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.04x
Industry
4.05x
AVTE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AVTE's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.4M
Profit Margin
0%
AVTE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$80.3M
Liabilities
$3.9M
Debt to equity
0.05
AVTE's short-term assets ($80.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AVTE's short-term assets ($80.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AVTE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AVTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
$13.1M
Financing
$554.0k
AVTE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AVTE vs Biotech Stocks
Aerovate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.